1. Home
  2. TVTX

TVTX

Travere Therapeutics Inc.

Logo Travere Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Founded: N/A Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 441.4M IPO Year: N/A
Target Price: $17.83 AVG Volume (30 days): 1.2M
Analyst Decision: Buy Number of Analysts: 14
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.50 EPS Growth: N/A
52 Week Low/High: $5.25 - $22.75 Next Earning Date: 05-02-2024
Revenue: $145,238,000 Revenue Growth: 32.69%
Revenue Growth (this year): 51.77% Revenue Growth (next year): 43.02%

Share on Social Networks: